Other Current Assets

9 Months Ended

Sep. 30, 2018

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets

4. Other Current Assets

As of September 30, 2018, Other Current Assets included prepaid expenses of $0.3 million, comprised primarily of prepaid insurance of $0.2 million and prepayments made to the Company’s clinical research organizations for our clinical trials for prexigebersen in AML and CML of $0.1 million. As of December 31, 2017, Other Current Assets included prepaid expenses of $0.4 million.